Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 2020

View Archived Issues

Janpix describes small-molecule monovalent STAT3 and STAT5 protein degraders

CStone Pharmaceuticals presents data on the CDK4/6 inhibitor CS-3002

Phase II/III study begins with mavrilimumab in severe COVID-19 pneumonia and hyperinflammation

Bayer initiates first-in-human study of BAY-2701439 in advanced HER2-expressing cancers

M-6223 studied in first-in-human trial for metastatic or locally advanced solid unresectable tumors

Akeso begins phase II study of AK-104 in recurrent or metastatic cervical cancer

Fe-isty cancer cells flourish in hostile subarachnoid space

DS-6157a demonstrates promising efficacy in preclinical models of GIST

Novartis reports first-in-human data for BLZ-945

Regeneron reports preclinical data on 89Zr-labeled REGN-5054 antibody for CD8+ T-cell monitoring

Array BioPharma identifies new protein kinase inhibitors

Patient enrollment begins in Ampion COVID-19 program

In vivo studies show potent reversal of anticoagulation with VMX-COO1

Topline phase III data for favipiravir in patients with COVID-19

Promising preclinical data for NurOwn-derived exosome-based therapy for COVID-19 ARDS

Kaleido Biosciences initiates second study of KB-109 in outpatients with COVID-19

FDA lifts clinical hold on all development of seladelpar

Cybrexa Therapeutics details development of peptide-drug conjugate CBX-13 for solid tumors

Sareum reports findings with TYK2/JAK1 inhibitors in disease model of lupus

Exonbio launches SARS-CoV-2 monoclonal antibodies for research

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...